On the stock market since 2018, it operates in the world of health and science. It has 1,004 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 14% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 24% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 9% a year on average.
Sales run at $211.1M a year. A small number, but proof the product has real buyers.
A loss of $51.1M against $211.1M in annual sales.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
On our five-subject report card, ESTA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ESTA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (50/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.